

oxidative stress as a common denominator. Such mechanistic understanding could further help to design pre-clinical and clinical studies.

[235] Schisandrin B prevents doxorubicin-induced chronic cardiotoxicity and enhances its anticancer activity in vivo

X. Hu¹, Y. Xu¹, J. Sun¹, Z. Liu¹, Q. Pan¹, F. Sun¹, Z. Yan¹, L. Li¹. ¹Second Affiliated Hospital, Cancer Institute, Hangzhou, China

Background: To mitigate the cardiotoxicity of anthracycline antibiotics without compromising their anticancer activities is still an issue to be solved. We previously demonstrated that schisandrin B (Sch B) could protect against doxorubicin (Dox)-induced acute cardiotoxicity via enhancing cardiomyocyte glutathione redox cycling that could attenuate oxidative stress generated from Dox. In this study, we attempted to prove if Sch B could also protect against Dox-induced chronic cardiotoxicity, a more clinically relevant issue, without compromising its anticancer activity.

Materials and Methods: Rat was given intragastrically either vehicle or Sch B (50 mg/kg) two hours prior to i.p. Dox (2.5 mg/kg) weekly over a 5-week period with a cumulative dose of Dox 12.5 mg/kg. At the 6th and 12th week after last dosing, rats were subjected to cardiac function measurement, and left ventricles were processed for histological and ultrastructural examination. Dox anticancer activity enhanced by Sch B was evaluated by growth inhibition of 4T1, a breast cancer cell line, and S180, a sarcoma cell line, in vitro and in vivo.

Results: Pretreatment with Sch B significantly attenuated Dox-induced loss of cardiac function and damage of cardiomyocyte structure. Sch B substantially enhanced Dox cytotoxicities toward S180 in vitro and in vivo in mice, and increased Dox cytotoxicity against 4T1 in vitro. Although we did not observe this enhancement against the implanted 4T1 primary tumour, the spontaneous metastasis to lung was significantly reduced in combined treatment group than Dox alone group.

Conclusion: Sch B is capable of protecting Dox-induced acute and chronic cardiotoxicity and enhancing its anticancer activity. To the best of our knowledge, Sch B is the only molecule ever proved to function as a cardioprotective agent as well as a chemotherapeutic sensitizer, which is potentially applicable for cancer treatment.

[236] Blockade of fatty acid synthase affects phosphatidylinositol-3 kinase signaling in ovarian cancer by ubiquitin-mediated degradation of downstream effector kinases

K. Tomek¹, H. Karlic², R. Wagner¹, C.F. Singer³, F. Varga⁴, T.W. Grunt⁵. ¹Medical University Vienna, Division of Oncology Department of Medicine I, Vienna, Austria, ²Hanusch Hospital, Ludwig Boltzmann Cluster Oncology, Vienna, Austria, ³Medical University Vienna, Division of Special Gynecology Department of Obstetrics/Gynecology, Vienna, Austria, ⁴Hanusch Hospital, Ludwig Boltzmann Institute Osteology, Vienna, Austria, ⁵Medical University Vienna & Ludwig Boltzmann Cluster Oncology, Division of Oncology, Department of Medicine I, Vienna, Austria

Ovarian carcinoma is fourth leading cause of cancer death in women and accounts for highest mortality of all gynecological malignancies. The phosphatidylinositol-3 kinase (PI3K) cascade controls proliferation, differentiation, tumorigenesis, angiogenesis and apoptosis. Many ovarian carcinomas harbor aberrations within the PI3K pathway. Amplification of PI3K is observed in ~40% of ovarian carcinomas and cell lines. The PI3K downstream target AKT phosphorylates mTOR, which is hyperactivated in many cancers. mTOR activates S6 via p70S6K, which is frequently activated in ovarian cancer. S6 protein being a component of the 40S ribosomal subunit is involved in translation control. mTOR also phosphorylates eukaryotic translation initiation factor 4E (eIF4E) inhibitor binding protein 1 (4EBP1). Phosphorylated 4EBP1 dissociates from eIF4E and activates cap-dependent mRNA translation. In addition, many ovarian carcinomas harbor aberrations of the ErbB receptors ErbB1 (EGFR; 55%) or ErbB2 (HER2/neu; 35%), respectively. Importantly, PI3K signaling plays crucial roles in transmitting ErbB-derived signals and stimulating cancer growth. Irrespectively, clinical studies yet reveal that monotherapies with ErbB1 or ErbB2 inhibitors or antibodies are largely inefficient in ovarian carcinomas. Therefore, additional molecular targeting strategies are urgently needed. Fatty acid synthase (FASN) being overexpressed in ~80% of ovarian carcinomas is a marker for poor prognosis. It supports formation of lipid rafts in the plasma membranes, which accommodate transmembrane growth factor receptors incl. ErbB proteins. Thereby, FASN facilitates signal generation at the cell membranes. Most importantly, inhibition of FASN delays disease progression of ovarian carcinoma xenografts. Recently, we reported that the FASN inhibitor C75 downregulates ErbB1 and ErbB2 in ovarian cancer and sensitizes the cells against ErbB targeting drugs (Grunt et al., BBRC, 385, 454). We now demonstrate that C75 abrogates A2780 ovarian cancer cell growth. This correlates with silencing of PI3K downstream signaling as evidenced by reduced phosphorylation of AKT, mTOR, p70S6K and 4EBP1 in Western blot analyses, which is caused by

both specific protein dephosphorylation/deactivation and by ubiquitin-mediated proteasomal degradation of these PI3K effector proteins. In contrast, specific phosphorylation/activation of the mitogen-activated protein kinase ERK1/2 is increased, although ERK1/2 steady-state levels are concurrently decreased by C75. In comparison, the PI3K inhibitor LY294002 blocks phosphorylation while concurrently upregulating steady-state levels of AKT, mTOR, p70S6K, and 4EBP1, and it activates ERK1/2. This suggests (i) that PI3K/AKT normally cross-inhibits ERK1/2, which can be abrogated by silencing of PI3K/AKT, and (ii) that PI3K, but not ERK1/2, signaling is crucial for growth arrest of ovarian cancer cells. Notably, our data demonstrate for the first time that C75-mediated silencing of PI3K signaling is caused by reduced phosphorylation and diminished protein stability due to increased ubiquitination and proteasomal degradation. Thus, C75 provides additive anticancer action, when compared to the PI3K inhibitor LY294002, which directly targets PI3K and downstream signaling, but does not stimulate effector protein degradation. In summary, FASN represents a promising anticancer drug target, which should be further developed for clinical use in ovarian carcinoma. Supp. 'Med.-Wiss. Fonds Bürgerm. Wien'.

[237] Splice variant profiling in relation to tamoxifen resistance in breast cancer

L.D. Zhang¹, Y.K. Chan¹, Y.C. Ip¹, W.H. Tsang¹, Y.N. Cheung¹, S.Y. Wong¹, U.S. Khoo¹. ¹The University of Hong Kong, Pathology, Hong Kong, China

Tamoxifen, a selective estrogen receptor modulator (SERM), is commonly applied to treat estrogen receptor (ER) positive breast cancers. However, some patients acquire resistance over prolonged treatment. The biological mechanism still awaits better understanding. Previously a number of gene expression profiling studies identified gene profiles that could predict cancer prognosis or characterize tamoxifen responsiveness, but there is little concordance between the genes identified. This may be due to pre-mRNA alternatively spliced variants that are not discriminated in conventional microarrays.

To identify the alternatively spliced variants that contribute to tamoxifen resistance, SpliceArrayTM profiling (ExonHit Therapeutics, Inc.) on 417 breast cancer related genes was performed in a panel of breast cancer cell lines. Splice variants that were differentially expressed between parental tamoxifen-sensitive (TamS) and derived tamoxifen-resistant (TamR) cell lines were identified and validated by real time-quantitative PCR.

Splice variant BQ323636.1 of NCOR2 (Nuclear receptor co-repressor 2) was successfully validated in cell lines and clinical samples. In presence of tamoxifen, the mRNA expression level ratio of variant (BQ323636.1) versus wild type form (NM_006312.2) was significantly higher in derived TamR cell line AK47 compared to its parental TamS cell line ZR75-1. In 26 Chinese breast cancer patient RNA samples, the ratio positively correlated with metastasis.

NCOR2 is a component of the histone deacetylase-containing protein complex. It is recruited by tamoxifen to repress the transcription activation activity of ER α . Exon 11 skip in BQ323636.1 variant results in early termination of the protein product. Only the first repression domain at the N-terminal is retained while 3 repression domains and 2 nuclear receptor-interacting domains are lost, indicating its disability of binding to nuclear receptors. Thus, this variant may inhibit the repression on ER α transcription activation by competing with its wild type form for interacting with other protein partners in the HDAC complex. This may hinder the recruitment of HDAC complex to the target gene promoter and suppress the antagonist effect of tamoxifen, leading to tamoxifen resistance. Ongoing functional studies are being performed to confirm this possible mechanism, which may serve as a potential therapeutic target to overcome acquired tamoxifen resistance in breast cancer.

[238] The effects of proanthocyanidins on cardiotoxic and antitumour activity of doxorubicin

G. Bogdanovic¹, N. Andric², B. Stanic², J. Canadanovic-Brunet³, M. Spasic⁴, T. Jovanovic⁵, V. Baltic⁶. ¹Oncology Institute of Vojvodina, Experimental Oncology, Sremska Kamenica, Serbia, ²University of Novi Sad, Department of Biology and Ecology, Novi Sad, Serbia, ³University of Novi Sad, faculty of Technology, Novi Sad, Serbia, ⁴Institute for Biological Research "Sinisa Stankovic", Department of Physiology, Belgrade, Serbia, ⁵Medical faculty, Institute of Physiology, Belgrade, Serbia, ⁶Oncology Institute of Vojvodina, Clinic for Internal Medicine, Sremska Kamenica, Serbia

Background: Mechanisms of proanthocyanidin (PRO) activity are primarily associated with their antioxidative effects. As direct antioxidative action cannot explain positive effects of PRO in prevention of cancer and heart damage, we used different *in vivo* and *in vitro* models and combination of doxorubicin (DOX) and PRO to find out whether and how low doses of PRO could modulate DOX antitumour activity and achieve cardioprotection after DOX treatment.

Material and Methods: PROs were extracted from grape seeds by ethylacetate and water. Ehrlich ascitic and solid tumours were induced in Hann:NMRI mice. Free radical scavenging activity of PRO was determined by electron spin resonance (ESR) spectrometer. NADPH:cytochrome P450

reductase activity was measured by the method based on cytochrome c reduction in the presence of NADPH. Antioxidative enzymes in tissue and circulation (SOD, CAT, GR, and GST) were analyzed by standard procedures; enzymes, markers of tissue necrosis, were determined by commercial assays. Apo-direct assay was used for apoptosis detection.

Results: Proanthocyanidins did not prevent tumour development, but they influenced tumour growth dynamics. Mice treated with PRO/DOX combination developed neither ascitic nor solid tumours. PRO significantly prolonged survival of mice treated with DOX/PRO combination. Proanthocyanidins inhibited *in vitro* ESR signal of DOX semiquinone radical, and competitively inhibited activity of NADPH:cytochrome P450 reductase. Proanthocyanidins modified antioxidative enzymes activity and modulated their activity in rat heart and circulation 48 hours after DOX treatment. Proanthocyanidins synergistically increased DOX-induced apoptosis in Ehrlich ascitic tumour cells.

Conclusions: Obtained results indicated that effects of PRO are multiple and complex and PRO should not be treated only as free radical scavengers. Proanthocyanidins decreased DOX cytotoxicity but did not compromise its antitumour activity. The underlying molecular mechanism of this effect was inhibition of P450 reductase by PRO that resulted in decreased metabolic transformation of DOX followed by smaller production of reactive oxygen species. These results indicated that, for the PRO effects observed in our model system, activity in decreasing production of DOX metabolites and ROS reactive oxygen species was even more important than direct free radical scavenging activity of PRO.

[239] 15-deoxy-delta-12,14-Prostaglandin-J2 inhibits multidrug resistance genes and induces apoptosis in doxorubicin-resistant ovarian carcinoma cells

J. Prakash¹, P. Winkel¹, E. de Jong¹, K. Poelstra¹. ¹Groningen Research Institute for Pharmacy, Pharmacokinetics Toxicology and Targeting, Groningen, The Netherlands

Background: Development of chemoresistance in tumour cells is one of the biggest problems in cancer therapies. Multidrug resistance (*mdr1*) upregulation is known to be related to the activation of NF- κ B pathway in tumour cells. Recently, we have reported that 15-deoxy-delta-12,14-Prostaglandin-J₂ (15d-PGJ₂), a peroxisome proliferator-activated receptor-gamma (PPAR- γ) agonist, induces cell death in non-resistant tumour cells by inhibiting at least partly the NF- κ B activity and exhibited antitumour effects *in vivo*. In the present study, we investigated whether 15d-PGJ₂ could also inhibit NF- κ B pathway in doxorubicin-resistant ovarian carcinoma cells and thereby induce apoptosis and inhibit *mdr1* expression.

Material and Methods: Human ovarian carcinoma cell lines, A2780 (non-resistant) and A2780/AD (doxorubicin-resistant), were used for this study. The cell viability was evaluated using Alamar blue assay by incubating with 15d-PGJ₂ and other compounds for 48h in serum-free medium. To determine the NF- κ B and caspase-3/7 activities, a plasmid-based Luciferase reporter assay and a luminescence assay were used, respectively. Gene expression levels were determined through quantitative real-time PCR.

Results: Doxorubicin-resistant A2780/AD cells had significantly higher expression of *mdr1* and enhanced NF- κ B activity compared to the non-resistant A2780 cells. Treatment with 15d-PGJ₂ induced cell death in both A2780 and A2780/AD cells with a similar potency (IC₅₀=5.0 μ M). The effects were found to be PPAR γ -independent as an irreversible PPAR γ antagonist GW9662 could not block these effects. Also, 15d-PGJ₂ significantly enhanced the caspase-3/7 enzyme activity in both cell types indicating its caspase-mediated apoptotic activity. Furthermore, we found that 15d-PGJ₂ significantly inhibited the NF- κ B activity either inherent or induced with TNF- α in these cells. At a low dose (2.5 μ M), 15d-PGJ₂ significantly inhibited the expression of drug resistant-related genes (*mdr1* and *sirt1*) and antiapoptotic genes (*bcl-2* and *bcl-xl*) in A2780/AD cells. Treatment with a specific NF- κ B inhibitor BAY11-7082 only inhibited *mdr1* and *sirt1* gene expression but not of *bcl-2* and *bcl-xl*. These data suggest that inhibition of the drug resistance regulating genes by 15d-PGJ₂ is mediated through the blockade of the NF- κ B pathway.

Conclusion: The present study demonstrates that 15d-PGJ₂ can induce apoptosis in doxorubicin-resistant ovarian tumour cells and also inhibits multidrug resistance-regulating genes. Therefore, 15d-PGJ₂ is in potential a promising therapeutic agent for the treatment of chemoresistant tumours.

[240] Inhibition of cell survival, tumour growth and histone deacetylase (HDAC) activity by the dietary flavonoid luteolin in human epithelioid cancer cells

R. Iratni¹, S. Attoub², A.H. Hassan³, B. Vanhoecke⁴, A.M. Gaben⁵, M. Bracke⁴, M. Al-Sultan⁶, K. Arafat⁶, C. Gespach⁷, G. Petroianu⁸. ¹UAE University, Biology, Al Ain, U.A.E., ²College of Medicine and Health Sciences UAE University, Department of Pharmacology, Al Ain, U.A.E., ³College of Medicine and Health Sciences UAE University, Department of Biochemistry, Al Ain, U.A.E., ⁴University Hospital De Pintelaan 185, Laboratory of Experimental Cancer Research, Gent, Belgium, ⁵INSERM U673 and U938, University Pierre et Marie Curie Paris VI Hospital Saint-Antoine, Paris Cedex 12, France, ⁶College of Medicine and Health Sciences UAE University, Department of Pharmacology, Al Ain, U.A.E., ⁷University Pierre et Marie Curie Paris VI Hospital Saint-Antoine, INSERM U673 and U938, Paris Cedex 12, France, ⁸College of Medicine and Health Sciences UAE University, Department of Pharmacology, Al Ain, U.A.E.

Phytochemical compounds and histone deacetylase (HDAC) inhibitors are emerging as a new generation of anticancer agents with limited toxicity in cancer patients. The present study investigates the impact of luteolin, a dietary flavonoid, on survival, motility, invasion of cancer cells, and tumour growth *in vivo*. We found that luteolin (25–200 mM) decreased the viability of human cancer cell lines originating from the lung (LNM35), colon (HT29), liver (HepG2) and breast (MCF7). Luteolin effectively increased the sub-G1 fraction of apoptotic cells through caspases 3 and 7-dependent pathways. The effect of luteolin on cell-cell adhesion, motility and invasion was investigated using slow aggregation, wound healing, collagen type I and chick heart invasion assays, no effect on intercellular adhesion and motility was observed at non toxic concentration. However, the effect of luteolin on cell invasion seem to be highly tissue and cell type-dependent since luteolin was ineffective to reverse the invasive potential of LNM35, but inhibit the invasiveness of MCF-7/6 cells. Moreover, we demonstrated that luteolin is a potent HDAC inhibitor and that it potentiates the cytotoxicity of cisplatin in cultured LNM35 cells and decreased the growth of LNM35 tumour xenografts after intra-peritoneal injection (20 mg/kg) in athymic mice. Taken together, our data indicate that luteolin is a promising HDAC inhibitor for the treatment of lung cancer in combination with standard anticancer drugs such as cisplatin.

[241] L-2-oxothiazolidine-4-carboxylate reverses the growth-promoting effect of growth factors, improving the oxaliplatin antitumour response in WiDr colon cancer cells

A. Alonso-Varona¹, M. Caramés², I. García-Alonso², T. Palomares². ¹University Pais Vasco, Department of Cell Biology and Histology, Leioa Vizcaya, Spain, ²University Pais Vasco, Department of Surgery and Radiology, Leioa Vizcaya, Spain

Background: A common cause of treatment failure in colorectal cancer is chemoresistance, which may be related to the redox state of cancer cells and the tumour microenvironment, where growth factors (GFs) play an important role. Glutathione (GSH), a key regulator of the redox balance, is involved in GF signalling systems and may also protect against drug-induced cellular injury.

Materials and Methods: The effect of L-2-oxothiazolidine-4-carboxylate (OTZ, a GSH modulator) on oxaliplatin activity in the WiDr colon cancer cell line was studied. Cell proliferation and GSH content were assessed. Cells were exposed to the OTZ before treatment with oxaliplatin in the presence of either hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF) or epidermal growth factor (EGF).

Results: Exposure to GFs significantly increased GSH levels and induced a pro-tumour effect. During the first 48 h of incubation, GFs induced a near 20% reduction in oxaliplatin antitumour activity. Treatment with OTZ abrogated the growth-promoting effects of GFs and increased the antitumour effect of oxaliplatin. Moreover, the enhancement of oxaliplatin-induced growth inhibition produced by OTZ pretreatment was observed at 24 h with approximately a 30% increase being noted with respect to drug activity in the presence of GFs. In fact, this combination resulted in a dose modification factor (DMF) of 2, 1.3 and 1.5, in the presence of HGF, VEGF and EGF, respectively at 24 h, indicating an apparent synergistic effect ($P < 0.001$). At 72 h the combined therapy resulted in a 2.5-fold reduction ($P < 0.001$) in the proliferation rate compared with controls (DMF of nearly 0.9).

Conclusion: GSH manipulation by OTZ could yield a therapeutic gain for chemotherapy with oxaliplatin in the presence of GFs.

This work has been supported by grants of the University of the Basque Country/EHU, Basque Government and the Jesús Gangoiti Barrera Foundation.